Stage <scp>II</scp> desmoplastic melanoma treated with neoadjuvant immunotherapy and Mohs micrographic surgery-Reference-Cited by-同舟云学术

Stage II desmoplastic melanoma treated with neoadjuvant immunotherapy and Mohs micrographic surgery

Published:2022-10-29 Issue:3 Volume:37 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Lewis Daniel J.¹^ORCID,Zhang Junqian¹,Elenitsas Rosalie¹,Shanti Rabie M.²³,Miller Christopher J.¹,Cohen Justine V.⁴

Affiliation:

1. Department of Dermatology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

2. Department of Oral & Maxillofacial Surgery and Pharmacology, School of Dental Medicine University of Pennsylvania Philadelphia Pennsylvania USA

3. Department of Otorhinolaryngology/Head and Neck Surgery Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

4. Department of Oncology Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18669

Reference5 articles.

1. The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges

2. High response rate to PD-1 blockade in desmoplastic melanomas

3. Desmoplastic melanoma: demographic and clinicopathological features and disease‐specific prognostic factors;Shi P;Oncol Lett,2019

4. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

5. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)